Pyxis Oncology, Inc. Common Stock (PYXS) Stock Price
PYXSStock
$3.06+120.90%52W
Market Cap$255.23M
P/E—
PEG Ratio—
Div yield—
Beta1.32
PYXS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)104.81%
Price vs S&P 500 (4W)-1.33%
VGM Score56.43
PYXS Earnings Surprise History
Q2 25-0.30est. -0.35
Q3 25-0.35est. -0.34
Q4 25-0.29est. -0.34
Q1 26-0.37est. -0.35
Q2 26-0.40est. -0.35
PYXS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.38
4.33
4.33
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PYXSPyxis Oncology, Inc. Common Stock | — | D | A | $3.06 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Pyxis Oncology, Inc. Common Stock
Pyxis Oncology is a preclinical-stage company developing next-generation therapeutics targeting difficult-to-treat cancers. The company's dual approach combines direct tumor cell killing with addressing underlying cancer pathologies that enable proliferation and immune evasion. This strategy aims to improve treatment outcomes for patients with limited options.